Fallout from the Third Circuit’s decision in June establishing GlaxoSmithKline as a corporate citizen of Delaware, not Pennsylvania, could land back in the appeals court.
The chief judge of the Middle District of Pennsylvania has certified for interlocutory appeal a question on which district judges have split since the U.S. Court of Appeals for the Third Circuit issued that June opinion, which had the effect of preserving the pharmaceutical giant’s ability to remove cases filed against it in the Pennsylvania state courts to federal court based on diversity jurisdiction.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
